Seeking Alpha


Send Message
View as an RSS Feed
View ajbrzoz's Comments BY TICKER:
Latest comments  |  Highest rated
  • Genocea's GEN-003 Reviewed By An Immunologist- This Week In Pharma Controversies Investigated [View article]
    Long $GNCA.
    Jun 19, 2015. 06:50 PM | Likes Like |Link to Comment
  • Northwest Biotherapeutics: Encouraging Survival Results In 51 Glioblastoma Multiforme Patients [View article]
    Thanks for the article. I'm long CLDX vs. NWBO because CLDX pipeline is broad and deep (Rindo; Glemba; Varli; CDX-1401; CDX-301; & CDX-014), & they have combo trials of Varli w/ Roche & BMY. CLDX management is also a big plus. At around $28 PPS, CLDX is still way undervalued compared to JUNO and KITE.

    June 2015 should be a pivotal mth for CLDX, with ReACT readout expected and ASCO.
    Mar 31, 2015. 11:34 AM | 2 Likes Like |Link to Comment
  • Clinical Trial Hold Of Geron's Revolutionary Drug Imetelstat Will Be Temporary [View article]
    Great article! Thanks!
    Mar 18, 2014. 11:35 AM | Likes Like |Link to Comment
  • Arrowhead: There Is Still Plenty Of Room For Share Price Appreciation [View article]
    Thanks for a great article. ARWR was the Baker Bros #1 largest new position initiated 9/30/13, which says a lot for the confidence in where this company is headed:;archiveDateIn=
    Feb 7, 2014. 01:16 PM | 1 Like Like |Link to Comment
  • Why The FDA Got It Wrong And Why It Will Approve Vascepa For ANCHOR SNDA Submission [View article]
    You have said repeatedly that Amarin is dead, yet, you keep coming back to comment. If you really believed Amarin was dead and that Vascepa only had a 0.0001% chance of gaining ANCHOR approval, you wouldn't be here. I think you are worried that Vascepa will get ANCHOR because you know that AdCom was a circus.
    Nov 19, 2013. 08:10 PM | 4 Likes Like |Link to Comment
  • Why The FDA Got It Wrong And Why It Will Approve Vascepa For ANCHOR SNDA Submission [View article]
    PSalerno, are you kidding? The new guidelines will double the use of statins.
    Nov 19, 2013. 04:47 PM | 2 Likes Like |Link to Comment
  • Why The FDA Got It Wrong And Why It Will Approve Vascepa For ANCHOR SNDA Submission [View article]
    Hatvani, speaking up is better than remaining silent, especially when it's obvious that the FDA has done AMRN wrong.
    Nov 19, 2013. 08:28 AM | 17 Likes Like |Link to Comment
  • AMRN: Does The FDA Need To Be Investigated  [View instapost]
    The Vascepa AdCom Panel ties to industry should be investigated as it appears that Amarin was led to the gallows without a fair trial.
    Oct 22, 2013. 02:45 AM | 2 Likes Like |Link to Comment
  • New Study: EPA Reduces Cardiovascular Events - Enough For Amarin Approval? [View article]
    Great article!! I found it on Pubmed about a month ago and posted it on Stocktwits and Twitter. Great to see it make it to Seeking Alpha.
    Oct 21, 2013. 06:03 PM | 1 Like Like |Link to Comment
  • Amarin falls as investors digest advisory committee briefing documents [View news story]
    It was going to fall today, whether the doc's were good or bad. In this case, the briefing doc's are very good for AMRN's case for Vascepa's ANCHOR indication journey. Case in point, here's the last paragraph in Section 6 Conclusion, pp 103-104, "Patients who are at high risk for CVD who are taking statin therapy and have persistently high TGs are at-risk and need a safe and effective therapy that can be added to their statin therapy for more aggressive and comprehensive lipid control. If approved, Vascepa would fill an important unmet medical need for these patients."
    AdCom vote will be unanimous in favor of.
    Oct 13, 2013. 09:31 AM | 1 Like Like |Link to Comment
  • Make It Or Break It Day Could Be At Hand For Amarin [View article]
    While the Vascepa ANCHOR AdCom is very important for AMRN, PDUFA is the golden ticket.
    Oct 11, 2013. 08:15 AM | 6 Likes Like |Link to Comment
  • The Biotech Merger And Acquisition Buzz List [View article]
    AMRN will be bought before any company you mentioned in this article.
    Oct 3, 2013. 11:02 PM | 1 Like Like |Link to Comment
  • Drop The Anchor And Fish For Profits [View article]
    Why would BP wait until REDUCE-IT results are announced, when AMRN has ANCHOR in hand and the door is open to 40M+ patients in the US. Compare and contrast the trial designs, populations, diets, and EPA doses in REDUCE-IT and JELIS, and the question should be: "What opportunities will unfold with positive REDUCE-IT results?"

    PS- and don't forget the Vascepa/Statin combo product.
    Oct 2, 2013. 12:57 PM | 3 Likes Like |Link to Comment
  • AstraZeneca - Small Deal With Amplimmune Provides No Quick Fixes [View article]
    Can't fathom why AZN bought OMTH instead of AMRN. AMRN would be a quick and long term fix for AZN, with AMRN's pending ANCHOR labeling expansion for Vascepa, patent protection to 2030, statin/Vascepa combo product(s) dev't, and anticipated positive REDUCE-IT results upon study completion.
    Aug 27, 2013. 09:44 AM | Likes Like |Link to Comment
  • Amarin Update After CC [View instapost]
    Good summary. Just a wild guess, but I'm thinking BO price will be $35+ per share.
    Aug 11, 2013. 01:52 PM | 2 Likes Like |Link to Comment